News >

TAS-102 Continues to Demonstrate Efficacy, Safety in CRC and Gastric Cancers

Kristi Rosa
Published: Monday, Jun 24, 2019

Howard S. Hochster, MD

Howard S. Hochster, MD

Results from a pooled safety analysis of phase III trials of TAS-102 (trifluridine/tipiracil; Lonsurf) show that the agent can be used in patients with colorectal cancer (CRC) and gastric/gastroesophageal junction (GEJ) cancer alike with similar rates of efficacy and toxicity.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication